People with a specific variation in a gene that helps control the immune system are less likely to develop Parkinson’s disease and other neurological disorders, a new study reports. Scientists think that people carrying this genetic variant might benefit from vaccines that could help to delay the progression of…
Serina Therapeutics will merge with a wholly-owned subsidiary of AgeX Therapeutics to advance SER-252 (POZ-apomorphine), Serina’s lead treatment candidate for advanced Parkinson’s disease. The company will continue under the Serina name and expects to submit an investigational new drug application (IND) for SER-252 to the U.S. Food…
NE3107, BioVie’s experimental oral therapy for Parkinson’s disease, is showing promise as a first-line therapy to ease motor symptoms and as a possible strategy to enhance the benefits of standard carbidopa and levodopa therapy. According to data from a Phase 2 clinical trial and a preclinical study with…
A high dose of the investigational oral therapy mesdopetam led to a significant and clinically meaningful reduction in levodopa-induced dyskinesia — the uncontrolled, involuntary movements and muscle stiffness common in Parkinson’s disease patients undergoing treatment — in a Phase 2 study, according to an in-depth examination of trial…
A mutation in the GBA1 gene is associated with an increased risk of Parkinson’s disease among people of African ancestry, a new study shows. While other mutations in GBA1 have previously been linked with Parkinson’s, this mutation, which is particularly common in people of African ancestry, has not been associated before with…
Early results from a Phase 2 clinical trial testing lixisenatide, a medication used to treat diabetes, in people with Parkinson’s disease, indicate the treatment may slow the progression of motor symptoms. The LixiPark (NCT03439943) trial is evaluating lixisenatide’s effectiveness as add-on therapy in 156 people with early…
ND0612, a formulation of levodopa/carbidopa delivered continuously under the skin by a pump, was more effective than standard oral levodopa/carbidopa at controlling motor symptoms of Parkinson’s disease without causing problematic side effects. Those top-line findings from the Phase 3 BouNDless clinical trial were announced earlier this year,…
Aspen Neuroscience will use Rune Labs’ digital health platform to remotely collect data from Parkinson’s disease patients currently enrolled in a screening study. The goal of the Trial-Ready Cohort Screening study is to provide a comprehensive view of the disease ahead of patient recruitment for Aspen’s…
P2B001, an investigational combination therapy (pramipexole/rasagiline) from Pharma Two B, controlled Parkinson’s disease symptoms better than either of its individual components regardless of patients’ age or disease severity, according to subgroup analyses from a Phase 3 trial. As with previous analyses involving all participants, P2B001 was as effective…
Gain Therapeutics’ GT-02287, an oral investigational therapy for Parkinson’s disease, was found to reduce blood levels of neurofilament light chain (NfL), a biomarker of nerve cell degeneration, in mouse models of the disorder. Further, the treatment lessened recognizable features associated with Parkinson’s symptoms — such as alpha-synuclein…
Get regular updates to your inbox.
